IP Library › Granted Patent US 7,745,198
Granted Patent B2
US 7,745,198 · App. 10/532,412 · Granted Jun 29, 2010

Method of producing macrolide compound

Assignees: Mercian Corporation; Eisai R&D Management Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,745,198
App. No.
10/532,412
Granted
Jun 29, 2010
Kind
B2
Abstract

The present invention provides a novel method of producing the 12-membered ring macrolide compound 11107D having an antitumor activity by biological transformation. Starting material which is the 12-membered ring macrolide compound 11107B represented by the formula (I) is incubated in the presence of a strain belonging to the genus Mortierella , the genus Streptomyces or the family Micromonosporaceae (for example, Streptomyces sp. AB-1704 strain (FERM BP-8551)), each of which has the ability of transforming the 12-membered ring macrolide compound 11107B into a 11107D substance represented by the formula (II), or a preparation of its cultured myceha and oxygen, and then 11107D substance which is a target material is collected from the treating solution.

Claims (9)

1. A method of producing the macrolide compound 11107D represented by the formula (II):

by a biological transformation method, wherein said method of producing the macrolide compound 11107D comprises the steps of:

providing the macrolide compound 11107B represented by the formula (I):

mixing the macrolide compound 11107B represented by the formula (I) with a strain having an ability of conducting the above-mentioned biological transformation method and belonging to the genus Mortierella , the genus Streptomyces or the family Micromonosporaceae or a preparation of its cultured mycelia;

incubating the mixture obtained in the preceding mixing step; and

collecting the macrolide compound 11107D represented by the formula (II) from the incubated solution obtained in the preceding incubating step.

2. The production method according to claim 1 , wherein the strain belonging to the genus Streptomyces is Streptomyces sp. AB-1704 strain (FERM BP-8551), A-1544 strain (FERM BP-8446) or A-1545 strain (FERM BP-8447).

3. An isolated or purified culture of Streptomyces sp. AB-1704 strain (FERM BP-8551) having the ability of transforming the macrolide compound 11107B represented by formula (I)

into the macrolide compound 11107D represented by formula (II)

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2007
From: EISAI CO., LTD.
To: EISAI R&D MANAGEMENT CO., LTD.
Reel/Frame 019500/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2005
From: OKUDA, AKIFUMI; YAMAMOTO, SATOSHI; SAKAI, TAKASHI; TAKEDA, SUSMU; NAKASHIMA, TAKASHI; KANEKO, KATSURA; SAMESHIMA, TOMOHIRO; KATO, TAIRA; KAWAMURA, NAOTO
To: MERCIAN CORPORATION; EISAI CO., LTD.
Reel/Frame 016933/0451 →
Priority Claims (1)
JP 2002-346796 · Nov 29, 2002 · national
Continuity (1)
Related Publication 20060141589A1 · Jun 29, 2006